Therapeutic use of Tpl2 inhibitors has been suggested to impede prolonged and uncontrolled inflammation in diseases such as rheumatoid arthritis and inflammatory bowel disease based on preliminary studies in mice [26], [34]–[36]. The gene discussed is MAP3K8; the disease is inflammatory bowel disease.